“By the summer of 2020, front-line physicians had discovered another COVID remedy that equalled HCQ in its staggering, life-saving efficacy. Five years earlier, two Merck scientists won the Nobel Prize for developing ivermectin (IVM), a drug with unprecedented firepower against a wide range of human parasites, including roundworm, hookworm, river blindness, and lymphatic filariasis. That salute was the Nobel Committee’s only award to an infectious disease medication in 60 years. FDA approved IVM as safe and effective for human use in 1996. WHO includes IVM (along with HCQ) on its inventory of “essential medicines”—its list of remedies so necessary, safe, efficacious, and affordable that WHO deems easy access to them as essential “to satisfy the priority health care needs of the population.”2 WHO has recommended administering ivermectin to entire populations to treat people who might have parasitic infections—meaning they consider it safe enough to give to people who haven’t even been diagnosed. Millions of people have consumed billions of IVM doses as an anti-parasitic, with minimal side effects. Ivermectin’s package insert suggests that it is at least as safe as the most popular over-the-counter medications, including Tylenol and aspirin. Researchers at Japan’s Kitasato Institute published a 2011 paper describing IVM in terms almost never used for any other drug: There are few drugs that can seriously lay claim to the title of “Wonder drug,” penicillin and aspirin being two that have perhaps had greatest beneficial impact on the health and wellbeing of Mankind. But ivermectin can also be considered alongside those worthy contenders, based on its versatility, safety, and the beneficial impact that it has had, and continues to have, worldwide—especially on hundreds of millions of the world’s poorest people. Three statues—at the Carter Center, at the headquarters of the World Bank, and at the headquarters of the World Health Organization—honor the development of ivermectin. Because since 2012, multiple in-vitro studies have demonstrated that IVM inhibits the replication of a wide range of viruses. Nature Magazine published a 2020 study reviewing 50 years of research finding IVM “highly effective against microorganisms including some viruses,” and reporting the results in animal studies demonstrating “antiviral effects of ivermectin in viruses such as Zika, dengue, yellow fever, West Nile . . .”

An April 3, 2020 article entitled “Lab experiments show anti-parasitic drug, ivermectin, eliminates SARS-CoV-2 in cells in 48 hours,” by Australian researchers at Monash and Melbourne Universities and the Royal Melbourne Hospital, first won IVM global attention as a potential treatment for COVID. The international press initially raved that this safe, inexpensive, well-known, and readily available drug had demolished SARS-CoV-2 in cell cultures. “We found that even a single dose could essentially remove all viral RNA by 48 hours and that even at 24 hours there was a really significant reduction in it,” said lead researcher Dr. Kylie Wagstaff. Based on this study, on May 8, 2020, Peru—then under siege by a crushing COVID endemic— adopted ivermectin in its national guidelines. “Peruvian doctors already knew the medicine, widely prescribed it for parasites, and health authorities knew it was safe and were comfortable with it,” recalls Dr. Pierre Kory. COVID deaths dropped precipitously—by 14-fold—in the regions where the Peruvian government effectively distributed ivermectin. Reductions in deaths correlated with the extent of IVM distributions in all 25 states. In December 2020, Peru’s new president, under pressure from WHO, severely restricted IVM availability and COVID cases rebounded with deaths increasing 13-fold. In prophylaxis studies, ivermectin repeatedly demonstrated far greater efficacy against COVID than vaccines at a fraction of the cost. In Argentina, for example, in the summer of 2020, Dr. Hector Carvallo conducted a randomized placebo-controlled trial of ivermectin as a preventative, finding 100 percent efficacy against COVID. Carvallo’s team found no infections among the 788 workers who took weekly ivermectin prophylaxis, whereas 58 percent of the 407 controls had become ill with COVID-19. A later observational study from Bangladesh—also investigating ivermectin as a pre-exposure prophylaxis against COVID-19 among health care workers—found nearly as spectacular results: only four of the 58 volunteers who took a minimal dose of ivermectin (12 mg once per month for four months) developed mild COVID-19 symptoms, compared to 44 of the 60 health care workers who had declined the medication. Furthermore, a 2021 study suggested that a key biological mechanism of IVM— competitive binding with SARS-CoV-2 spike protein—was not specific to any coronavirus variant and therefore, unlike vaccines, ivermectin would probably be effective against all future variants. As early as March 1, 2020, some front-line ICU and ER doctors began using ivermectin in combination with HCQ in early treatment protocols. Dr. Jean-Jacques Rajter, a Belgian physician working in Miami, began using the drug March 15 and immediately saw an uptick in recoveries. He published an excellent paper on June 9. Meanwhile, two Western physicians using ivermectin in Bangladesh also reported a very high rate of recoveries, even among patients in later states of illness. Since March 2020, when doctors first used IVM against COVID-19, more than 20 randomized clinical trials (RCTs) have confirmed its miraculous efficacy against COVID for both inpatient and outpatient treatment. Six of seven meta-analyses of IVM treatment RCTs completed in 2021 found notable reductions in COVID-19 mortality. The relevant studies “all showed significant benefit for high-risk outpatients,” says the eminent Yale epidemiologist Dr. Harvey Risch. The only studies where its performance was anything short of stellar were those that investigated its efficacy in patients in very late stages of COVID. But even late-stage patients showed benefits in almost all studies, although somewhat less dramatic. According to a 2020 review by McCullough et al., “Numerous clinical studies—including peer-reviewed randomized controlled trials—showed large magnitude benefits of ivermectin in prophylaxis, early treatment, and also in late-stage disease management. Taken together . . . dozens of clinical trials that have now emerged from around the world are substantial enough to reliably assess clinical efficacy and infer a signal of benefit with acceptable safety.” Early in January 2021, Dr. David Chesler, a geriatric specialist who had treated 191 infected patients since the previous spring at seven Virginia nursing homes, wrote to Dr. Fauci claiming that he had achieved a mortality rate of 8 percent using ivermectin—half (and 146,000 deaths less than) the US average in elder-care facilities. In his letter to Dr. Fauci, Chesler attached a peer-reviewed case study documenting reports of similar efficacy from other countries. Neither Dr. Fauci nor anyone else from NIAID replied to Dr. Chesler’s letter. The Annals of Dermatology and Venereology reported that in a French nursing home, all 69 residents—average age 90—and 52 staff survived a COVID-19 outbreak. As it turns out, they had all taken ivermectin for a scabies infestation. COVID decimated the surrounding community, but only seven elder home residents and four staff were affected, and all had mild illness. None required oxygen or hospitalization.

Research suggests that ivermectin may work through as many as 20 separate mechanisms. Among them, ivermectin functions as an “ionophore,” facilitating transfer of zinc into the cells, which inhibits viral replication. Ivermectin stops replication of COVID-19, seasonal flu, and many other viruses through this and other mechanisms. For example, a March 2021 study18 by Choudhury et al., found that “Ivermectin was found as a blocker of viral replicase, protease and human TMPRSS2, which could be the biophysical basis behind its antiviral efficiency.” The drug also reduces inflammation via multiple pathways, thereby protecting against organ damage. Ivermectin furthermore impairs the spike protein’s ability to attach to the ACE2 receptor on human cell membranes, preventing viral entry. Moreover, the drug prevents blood clots through binding to spike protein, and also deters the spike protein from binding to CD147 on red blood cells, which would otherwise trigger clumping. When patients take IVM before exposure, the drug prevents infection, which halts onward transmission, and helps protect the entire community. In March, 2021, a published study by Peter McCullough and 57 other front-line physicians from multiple countries found that “Our early ambulatory treatment regimen was associated with estimated 87.6 percent and 74.9 percent reductions in hospitalization and death.” Many other studies echo Dr. McCullough’s results. The average reduction in mortality, based on 18 trials, is 75 percent, according to a January 2021 meta-analysis presentation to the NIH COVID-19 Treatment Guidelines Panel. A WHO-sponsored meta-review of 11 studies likewise suggests ivermectin can reduce COVID-19 mortality by as much as 83 percent. “

Kennedy Jr., Robert F . The Real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health (Children’s Health Defense) (pp.117-122). Skyhorse. Edizione del Kindle.